Nyumbani › Limfoma ya Selu Kubwa za B Diffuse › Massachusetts › Boston
Majaribio ya kliniki ya Limfoma ya Selu Kubwa za B Diffuse katika Boston, MA
Masomo 16 ya Limfoma ya Selu Kubwa za B Diffuse yanatafuta washiriki katika vituo vya Boston na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
InaajiriHatua 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
InaajiriHatua 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
InaajiriHatua 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
InaajiriHatua 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
InaajiriHatua 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
InaajiriHatua 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
InaajiriHatua 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
InaajiriHatua 2
- Boston Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
InaajiriHatua 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
InaajiriUtafiti wa uchunguzi
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
InaajiriHatua 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
InaajiriHatua 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
InaajiriHatua 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
InaajiriHatua 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Majaribio ya Limfoma ya Selu Kubwa za B Diffuse katika miji mingine
- New York City, NYUtafiti 21
- Baldwin Park, CAUtafiti 19
- Chicago, ILUtafiti 18
- Houston, TXUtafiti 17
- Los Angeles, CAUtafiti 17
- Milwaukee, WIUtafiti 16
- Nashville, TNUtafiti 15
- Portland, ORUtafiti 15
- Philadelphia, PAUtafiti 15
- Durham, NCUtafiti 14
- Dallas, TXUtafiti 13
- Seattle, WAUtafiti 12
Masomo mengine katika Boston
- Saratani ya MatitiUtafiti 111
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 90
- Saratani (aina zote)Utafiti 86
- Kansari ya kolorektaliUtafiti 63
- Saratani ya MetastasiUtafiti 63
- Saratan ya MapafuUtafiti 62
- Kansari ya MayaiUtafiti 61
- Saratani ya ProstateUtafiti 59
- HuzuniUtafiti 52
- Saratani ya EndometrialUtafiti 50
- Kushindwa kwa MoyoUtafiti 44
- Leukemia ya Myeloid ya GhaflaUtafiti 44
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.